L04AImmunosuppressants
Untergruppen
- Selective immunosuppressantsL04AA
- Tumor necrosis factor alpha (TNF-alpha) inhibitorsL04AB
- Interleukin inhibitorsL04AC
- Calcineurin inhibitorsL04AD
- Sphingosine-1-phosphate (S1P) receptor modulatorsL04AE
- Janus-associated kinase (JAK) inhibitorsL04AF
- Monoclonal antibodiesL04AG
- Mammalian target of rapamycin (mTOR) kinase inhibitorsL04AH
- Complement inhibitorsL04AJ
- Dihydroorotate dehydrogenase (DHODH) inhibitorsL04AK
- Neonatal fragment crystallizable receptor (FcRn) inhibitorsL04AL
- Other immunosuppressantsL04AX
Wirkstoffe
- tacrolimusL04AD02
- everolimusL04AH02
- methotrexateL04AX03
- adalimumabL04AB04
- cyclosporineL04AD01
- tofacitinibL04AF01
- dimethyl fumarateL04AX07
- pomalidomideL04AX06
- leflunomideL04AK01
- pirfenidoneL04AX05
- ustekinumabL04AC05
- teriflunomideL04AK02
- fingolimodL04AE01
- sirolimusL04AH01
- azathioprineL04AX01
- tocilizumabL04AC07
- cladribineL04AA40
- etanerceptL04AB01
- infliximabL04AB02
- apremilastL04AA32
- eculizumabL04AJ01
- risankizumabL04AC18
- baricitinibL04AF02
- canakinumabL04AC08
- golimumabL04AB06
- alemtuzumabL04AG06
- belimumabL04AG04
- emapalumabL04AG09
- secukinumabL04AC10
- basiliximabL04AC02
- guselkumabL04AC16
- ixekizumabL04AC13
- siponimodL04AE03
- spesolimabL04AC22
- mirikizumabL04AC24
- ocrelizumabL04AG08
- sarilumabL04AC14
- thalidomideL04AX02
- abataceptL04AA24
- anakinraL04AC03
- bimekizumabL04AC21
- certolizumab pegolL04AB05
- natalizumabL04AG03
- ofatumumabL04AG12
- rozanolixizumabL04AL02
- upadacitinibL04AF03
- axatilimabL04AG19
- efgartigimod alfaL04AL01
- ozanimodL04AE02
- pegcetacoplanL04AJ03
- ravulizumabL04AJ02
- vedolizumabL04AG05
- zilucoplanL04AJ06
- avacopanL04AJ05
- belumosudilL04AA48
- daclizumabL04AC01
- danicopanL04AJ09
- rilonaceptL04AC04
- siltuximabL04AC11
- voclosporinL04AD03
- belataceptL04AA28
- brodalumabL04AC12
- crovalimabL04AJ07
- deucravacitinibL04AF07
- diroximel fumarateL04AX09
- mycophenolic acidL04AA06
- remibrutinibL04AA60
- satralizumabL04AC19
- sutimlimabL04AJ04
- tildrakizumabL04AC17
- ublituximabL04AG14
- abetimusL04AA22
- deuruxolitinibL04AF09
- efalizumabL04AG02
- monomethyl fumarateL04AX11
- pozelimabL04AJ11